Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
8431694
Reference Type
Journal Article
Title
Carmustine (BCNU) in the treatment of malignant tumors (Rumanian)
Author(s)
Gherman Gr.; Mirza, V; Lazarov, P
Year
1974
Is Peer Reviewed?
1
Journal
Oncologia
ISSN:
1390-0110
Volume
13
Issue
5
Page Numbers
421-428
Language
Romanian; Moldavian; Moldovan
Abstract
A treatment with BCNU (1,3 bis(2 chlorethyl) 1 nitrosourea) was applied in 89 patients suffering from Hodgkin's disease (19 cases), reticulolymphosarcoma (28 cases), bronchopulmonary carcinoma (30 cases), other solid tumors (12 cases). BCNU was administered by the oral route in enterosoluble capsules containing 25 mg. The total dose administered was 300 mg/m2. Patients received 2-9 such doses at intervals of 6-8 weeks. The treatment was efficient in 68.42% of the patients with Hodgkin's disease (13/19), in 39.28% of the reticulosarcomas (11/28), in 33.33% of the bronchopulmonary carcinomas (10/30) and in 16.66% of the other solid tumors (2/12). Two categories of side effects were observed: digestive (nausea and vomiting) in 42.69% of the patients and hematologic (leuko and thrombocytopenia with a late onset) in 12.35% of the cases.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity